Exhibit 10.46
Execution Version
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 24, 2025, is entered into by and among ADAPTIMMUNE THERAPEUTICS PLC, a public limited company registered under the laws of England and Wales with company number 09338148 (“Parent” and “Company”), ADAPTIMMUNE LLC, a Delaware limited liability company (“Adaptimmune US”), CM INTERMEDIATE SUB I, INC., a Delaware corporation (“Intermediate Sub I”), CM INTERMEDIATE SUB II, INC., a Delaware corporation (“Intermediate Sub II”), TCR2 THERAPEUTICS INC., a Delaware corporation (“TCR”), TRUCS Therapeutics Limited, a company registered under the laws of England and Wales with company number 11749031 (“TRUCS”), and ADAPTIMMUNE LIMITED, a private limited company registered under the laws of England and Wales with company number 06456741 (“Adaptimmune Limited ”; and, together with Parent, Adaptimmune US, Intermediate Sub I, Intermediate Sub II, TCR, TRUCS and Adaptimmune Limited, jointly and severally, individually or collectively, as the context may require, “Borrower”), the several banks and other financial institutions or entities parties to the Loan Agreement (as defined below) (each, a “Lender”, and collectively, the “Lenders”), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the “Agent”).
“First Amendment Effective Date” means the date that Borrower satisfies (meaning delivery of required documents or payment of sums owed) each of the conditions to effectiveness set forth in Section 4 of that certain First Amendment to Loan and Security Agreement dated as of March 24, 2025 by and among the Borrower, Agent and the Lenders.
“Board Approved Forecast” means (a) prior to the First Amendment Effective Date, the Original Plan, (b) from the First Amendment Effective Date through the reporting period ending February 28, 2026, the Revised Plan, and (c) from and after the reporting period ending March 31, 2026, the Original Plan as updated from time to time by Borrower, provided that such changes are prepared in good faith and based on assumptions reasonable at such time and delivered to the Agent in accordance with Section 7.1(i) hereof and deemed acceptable to Agent in its reasonable discretion.
“Increased Cash Reporting Period” means any week during which at any point Borrower fails to maintain aggregated cash of Twenty-Five Million Dollars ($25,000,000) or less.
“Revised Plan” means the monthly cash forecast delivered by Borrower to Agent on March 19, 2025.
“2.5Prepayment.
(a)At its option upon at least seven (7) Business Days prior written notice to Agent, Borrower may at any time voluntarily prepay all or a portion (such portion not to be less than Five Million Dollars ($5,000,000) and if greater shall be greater in increments of One Million Dollars ($1,000,000) in excess thereof) of the outstanding Advances by paying the entire outstanding principal balance (or such portion thereof), all accrued and unpaid interest thereon, all unpaid Lender’s fees and expenses due hereunder accrued to the date of the repayment (including, without limitation, the portion of the End of Term Charge applicable to the aggregate original principal amount of the Term Loan Advances being prepaid in accordance with Section 2.6(b)), together with a prepayment charge equal to the following percentage of the outstanding principal amount of such Advance amount being so prepaid: with respect to each Advance (a) if the principal amount of such Advance amounts is prepaid on or prior to the date which is twelve (12) months following the Closing Date, three percent (3.00%); (b) if the principal amount of such Advance amounts is prepaid after the date which is twelve (12) months following the Closing Date but on or prior to the date which is twenty-four (24) months following the Closing Date, two percent (2.00%); and (c) thereafter through the day before the Term Loan Maturity Date, one percent (1.00%) (each, a “Prepayment Charge”). If at any time Borrower elects to make a prepayment, and at such time, there are outstanding Advances under multiple Tranches, the Prepayment Charge shall be determined by applying the amount of such prepayment in the following order: first, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the latest initial funding date; second, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the next latest initial funding date and so on until the entire principal balance of all Advances made hereunder (and all accrued but unpaid interest thereon) is paid in full. Borrower agrees that the Prepayment Charge is a reasonable calculation of Lenders’ lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advances.
2
Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and the Prepayment Charge upon the occurrence of a Change in Control or any other prepayment hereunder.
Notwithstanding the foregoing, Agent and Lenders agree to waive (x) the Prepayment Charge if Agent and Lenders or their Affiliates (in their sole and absolute discretion) agree in writing to refinance the Advances prior to the Term Loan Maturity Date, and (y) the Prepayment Charge with respect to the Paydown Amount set forth in clause Section 2.5(b) above. Any amounts paid under this Section shall be applied by Agent to the then unpaid amount of any outstanding Secured Obligations (including principal and interest) in such order and priority as Agent may choose in its sole discretion acting reasonably. For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately subsequent Business Day.”
“2.6End of Term Charge.
(a)On any date that Borrower partially prepays the outstanding Secured Obligations pursuant to Section 2.5 (other than, for the avoidance of doubt, any partial prepayment that would result in all remaining outstanding Secured Obligations being prepaid in full), Borrower shall pay the Lenders a charge of equal to five and eighty-five hundredths percent (5.85%) multiplied by the aggregate principal amount of such Term Loan Advances being prepaid; provided, however, that this Section 2.6(a) shall not apply to payments made pursuant to Section 2.5(b), which shall be deferred and paid in accordance with Section 2.6(b).
(b)On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays in full the outstanding Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement), (iii) the date that the outstanding Secured Obligations become due and payable in full, Borrower shall pay Lenders (x) a charge equal to five and eighty-five hundredths percent (5.85%) multiplied by the aggregate original principal amount of such Term Loan Advances funded, plus (y) without duplication, a charge equal to five and eighty-five hundredths percent (5.85%) multiplied by the aggregate amount of payment made pursuant to Section 2.5(b)(1) such charge being in the amount of $1,462,500, minus (z) the aggregate amount of payments actually made pursuant to Section 2.6(a) (together, the “End of Term Charge”).
(c)Notwithstanding the required payment date of such End of Term Charge, the applicable pro rata portion of the End of Term Charge shall be deemed earned by Lenders as of each date that an applicable Term Loan Advance is made. For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.
3
“(m)commencing on March 31, 2025 and no less often than bi-weekly (i.e. once every two weeks) (or, during an Increased Cash Reporting Period, weekly (i.e. once every week)) thereafter, and in each case in form reasonably satisfactory to Agent, cash balance reports listing the latest balances of each Deposit Account and Securities Account of the Loan Parties and their respective Subsidiaries. The first such report shall be required to be delivered on or before March 31, 2025.”
“(a)maintain Qualified Cash in an amount greater than or equal to (i) the outstanding principal amount of the Term Loan Advances, multiplied by fifty percent (50%) (the “Minimum Cash Coverage Percentage”).
4
Borrower acknowledges having read and understood and hereby waives the benefits of Section 1542 of the California Civil Code, which provides as follows (and hereby waives the benefits of any similar law of the state that may be applicable):
“A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.”
Borrower acknowledges that the foregoing provisions of this Section 6 are intended to be a general release with respect to the matters described therein. Borrower does hereby expressly acknowledge and agree that the waivers and releases contained in this Amendment shall not be construed as an admission of and/or the existence of any claims of Borrower against Agent or Lender. Borrower does hereby acknowledge and agree that the value to Borrower of this Amendment and of the covenants and agreements on the part of Lender contained in this Amendment substantially and materially exceeds any and all value of any kind or nature whatsoever of any claims or liabilities waived or released by Borrower hereunder.
5
6
[remainder of page intentionally left blank]
7
IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first above written.
BORROWER:
ADAPTIMMUNE THERAPEUTICS PLC, an English public limited company:
By: /s/ Adrian Rawcliffe
Name: Adrian Rawcliffe
Title: Director
ADAPTIMMUNE LIMITED, an English private limited company
By: /s/ Gavin Wood
Name: Gavin Wood
Title: Director
TRUCS THERAPEUTICS LIMITED, an English private limited company
By: /s/ Gavin Wood
Name: Gavin Wood
Title: Director
ADAPTIMMUNE LLC, a Delaware limited liability company
Signature: /s/ Helen Tayton-Martin
Name:Helen Tayton-Martin
Title:President
[Signature Page to First Amendment to Loan and Security Agreement (Adaptimmune)]
CM INTERMEDIATE SUB I, INC., a Delaware corporation
Signature: /s/ William Bertrand
Name:William Bertrand
Title:President
CM INTERMEDIATE SUB II, INC., a Delaware corporation
Signature: /s/ William Bertrand
Name:William Bertrand
Title:President
TCR2 THERAPEUTICS INC., a Delaware corporation
Signature: /s/ William Bertrand
Name:William Bertrand
Title:President
[SIGNATURES CONTINUE ON THE NEXT PAGE]
[Signature Page to First Amendment to Loan and Security Agreement (Adaptimmune)]
AGENT:
HERCULES CAPITAL, INC.
Signature:/s/ Seth Meyer
Name:Seth Meyer
Title:Chief Financial Officer
LENDERS:
HERCULES CAPITAL, INC.
Signature:/s/ Seth Meyer
Name:Seth Meyer
Title:Chief Financial Officer
HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P.
By: Hercules Adviser LLC, its Investment Adviser
Signature:/s/ Seth Meyer
Name:Seth Meyer
Title:Authorized Signatory
HERCULES PRIVATE CREDIT FUND 1 L.P.
By: Hercules Adviser LLC, its Investment Adviser
Signature:/s/ Seth Meyer
Name:Seth Meyer
Title:Authorized Signatory
[Signature Page to First Amendment to Loan and Security Agreement (Adaptimmune)]